February 22, 2021

Duopharma Biotech Maintains Profit Momentum

➢ 4Q PBT leaps to RM20.47 million, a 47% increase over previous corresponding period
➢ EPS climbs to 8.46 sen for the year from previous corresponding year’s 8.25 sen
➢ The Government of Malaysia’s extension of existing Supply Agreements with government
hospitals, clinics stabilises a significant portion of group revenue, placing Duopharma Biotech
in a better position to mobilise resources to intensify foray into specialty and niche products
➢ Supply of Covid-19 vaccine also expected to contribute positively to future earnings